Increased levels of acylation-stimulating protein in interleukin-6-deficient (IL-6(-/-)) mice

Endocrinology
Ingrid WernstedtVille Wallenius

Abstract

IL-6-deficient (IL-6(-/-)) mice develop obesity at 6-7 months of age. To elucidate the mechanisms of this mature-onset obesity, global gene expression profiles of 3-month-old preobese IL-6(-/-) were compared with those of IL-6(+/+) mice using DNA arrays. Genes that were up-regulated in IL-6(-/-) mice included the factors transthyretin and properdin in white adipose tissue and adipsin in muscle. These factors have been shown to influence the formation of acylation-stimulating protein (ASP), a cleavage product of complement C3. ASP stimulates the synthesis of triacylglycerol in adipocytes, and ASP-deficient mice are resistant to diet-induced obesity. In line with the increases in transthyretin, properdin, and adipsin, ASP levels in serum were increased by 31-54% in IL-6(-/-) compared with IL-6(+/+) mice. Furthermore, IL-6 replacement treatment in IL-6(-/-) mice decreased ASP levels significantly by 25-60%. In conclusion, ASP levels are increased in preobese IL-6(-/-) mice. This increase may result in increased triacylglycerol formation and uptake in IL-6(-/-) adipocytes and thereby contribute to the development of obesity in IL-6(-/-) mice.

References

Oct 1, 1991·Canadian Journal of Physiology and Pharmacology·N J RothwellS J Hopkins
May 1, 1995·Endocrinology·K NonogakiK R Feingold
Apr 1, 1997·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·M MaslowskaK Cianflone
Aug 24, 1999·European Journal of Clinical Investigation·M MaslowskaK Cianflone
May 22, 2001·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·J SalehK Cianflone
Jan 12, 2002·Nature Medicine·Ville WalleniusJohn-Olov Jansson
Jun 11, 2002·Biochemical and Biophysical Research Communications·Kristina WalleniusJohn-Olov Jansson
Aug 16, 2002·The Journal of Physiology·Dorthe LyngsøJens Bülow
Sep 24, 2002·The Journal of Biological Chemistry·Zhunan XiaKatherine Cianflone
Jan 25, 2003·Biochimica Et Biophysica Acta·Katherine CianfloneLan Ying Chen
Apr 12, 2003·Pflügers Archiv : European journal of physiology·Bente Klarlund PedersenMark A Febbraio
Jun 6, 2003·Endocrine Reviews·José Manuel Fernández-Real, Wifredo Ricart
Jul 5, 2003·The Journal of Clinical Endocrinology and Metabolism·Gerrit van HallBente K Pedersen
Sep 13, 2003·The Journal of Clinical Endocrinology and Metabolism·Kaj StenlöfJohn-Olov Jansson
Oct 2, 2003·Expert Opinion on Biological Therapy·Kristina WalleniusVille Wallenius
Apr 23, 2005·Endocrinology·Peter J KloverRobert A Mooney
Feb 4, 2006·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Ingrid WernstedtJohn-Olov Jansson

❮ Previous
Next ❯

Citations

May 25, 2012·Immunobiology·Alexandre FisetteKatherine Cianflone
Jun 15, 2011·Wilderness & Environmental Medicine·Jessica D SmithMartin Noël
Jun 2, 2007·Peptides·Weihong Pan, Abba J Kastin
Apr 21, 2012·International Journal of Peptides·Diana R Engineer, Jose M Garcia
Feb 11, 2015·Biochimica Et Biophysica Acta·Yongjie MaDexi Liu
Aug 23, 2007·American Journal of Physiology. Endocrinology and Metabolism·Wei CuiKatherine Cianflone
Apr 24, 2012·Experimental Physiology·Anna BenrickIngrid Wernstedt Asterholm
Dec 28, 2007·American Journal of Physiology. Endocrinology and Metabolism·Sabina PaglialungaKatherine Cianflone
Jul 9, 2010·Endocrinology·Sarah A RobertsonDavid M Olson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Canavan Disease

Canavan disease, a type of leukodystrophy, is an autosomal recessive neurodegenerative disorder, and is one of the most common degenerative cerebral diseases of infancy. Discover the latest research on Canavan disease here.

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.